2022
DOI: 10.1080/19420862.2022.2031483
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Early humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus neutralization at mucosal sites. Given the essential roles of IgM and IgA in the control and elimination of SARS-CoV-2 infection, the mucosal immunity could be exploited for therapeutic and prophylactic purposes. However, almost all neutralizing antibodies that are authorized for emergency use and under clinical development are IgG antibodies,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
16
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 11 publications
(16 citation statements)
references
References 149 publications
(16 reference statements)
0
16
0
Order By: Relevance
“…Besides normal and specific human IVIg approaches, several other polyclonal approaches to therapy for COVID-19 have been attempted, including pooled equine antibodies from immunized horses, polyclonal IgY antibodies from immunized chickens [ 185 , 186 ], glyco-engineered polyclonal antibodies from immunized swine [ 187 189 ], orally-administered hyper-immune bovine IgG (NCT04682041 [ 7 ]) [ 190 ], pooled human IgG from immunized transgenic cows [ 191 ], pooled polyvalent mixture containing IgG, IgA, and IgM [ 192 , 193 ], and pooled recombinant human IgGs [ 194 , 195 ] (Table 1 ).…”
Section: Convalescent Patient and Polyclonal Therapeutic Approachesmentioning
confidence: 99%
See 4 more Smart Citations
“…Besides normal and specific human IVIg approaches, several other polyclonal approaches to therapy for COVID-19 have been attempted, including pooled equine antibodies from immunized horses, polyclonal IgY antibodies from immunized chickens [ 185 , 186 ], glyco-engineered polyclonal antibodies from immunized swine [ 187 189 ], orally-administered hyper-immune bovine IgG (NCT04682041 [ 7 ]) [ 190 ], pooled human IgG from immunized transgenic cows [ 191 ], pooled polyvalent mixture containing IgG, IgA, and IgM [ 192 , 193 ], and pooled recombinant human IgGs [ 194 , 195 ] (Table 1 ).…”
Section: Convalescent Patient and Polyclonal Therapeutic Approachesmentioning
confidence: 99%
“…SAB-185 is purified human IgG mixture from transgenic (tg) cows [ 198 , 199 ] immunized with plasmid DNA encoding SARS-CoV-2 spike protein, followed by booster immunizations with spike protein generated by insect cells. Prior to the COVID-19 pandemic, SAb Biotherapeutics had also evaluated SAB-301, a polyclonal mixture of human IgGs targeting middle east respiratory (MERS) virus, in Phase I clinical trials (NCT02788188 [ 7 ]) [ 193 ]. The potential upside of tg cattle-produced human IgGs is supply, consistency across lots, and the ability to vaccinate the cows with antigens not available for human vaccination due to regulatory and safety considerations.…”
Section: Convalescent Patient and Polyclonal Therapeutic Approachesmentioning
confidence: 99%
See 3 more Smart Citations